

2019 Future of Thromboembolism R&D Pipeline Drugs and Companies- Analysis of Global Thromboembolism Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/21D88AAD9F5EN.html>

Date: January 2019

Pages: 75

Price: US\$ 2,199.00 (Single User License)

ID: 21D88AAD9F5EN

Abstracts

The global demand for Thromboembolism treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Thromboembolism pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Thromboembolism pipeline companies from advancing their products into Phase 3 or Phase 4.

Thromboembolism Report Description

The H1 2019 pipeline review report on Thromboembolism pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Thromboembolism pipeline compounds.

The Thromboembolism pipeline guide presents information on all active drugs currently being developed for Thromboembolism. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Thromboembolism pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Thromboembolism drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Thromboembolism product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Thromboembolism pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Thromboembolism pipeline report includes

- An overview of Thromboembolism disease including symptoms, causes, diagnosis and available treatment options is provided.

- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

- Phase wise count of pipeline compounds

- Company wise list of pipeline compounds

- Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Thromboembolism pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Thromboembolism pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Thromboembolism pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL THROMBOEMBOLISM PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Report Guide and Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Thromboembolism Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
- 3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
- 3.4 Companies involved in Thromboembolism pipeline, H1- 2019
- 3.5 Mechanism of Action wise Thromboembolism Pipeline Candidates

4. ARROWHEAD PHARMACEUTICALS, INC THROMBOEMBOLISM PIPELINE DETAILS

- 4.1 Arrowhead Pharmaceuticals, Inc Business Profile
- 4.2 Arrowhead Pharmaceuticals, Inc Thromboembolism Drug Details
 - 4.2.1 Drug Snapshot
 - 4.2.1.1 Originator
 - 4.2.1.2 Collaborator/Co-Developer
 - 4.2.1.3 Route of Administration
 - 4.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 4.2.1.5 Area
 - 4.2.1.6 Type of Molecular Entity
- 4.3 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5. BAYER AG THROMBOEMBOLISM PIPELINE DETAILS

- 5.1 Bayer AG Business Profile
- 5.2 Bayer AG Thromboembolism Drug Details
 - 5.2.1 Drug Snapshot
 - 5.2.1.1 Originator
 - 5.2.1.2 Collaborator/Co-Developer
 - 5.2.1.3 Route of Administration
 - 5.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 5.2.1.5 Area
 - 5.2.1.6 Type of Molecular Entity
- 5.3 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6. CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. THROMBOEMBOLISM PIPELINE DETAILS

- 6.1 China Biologic Products Holdings, Inc. Business Profile
- 6.2 China Biologic Products Holdings, Inc. Thromboembolism Drug Details
 - 6.2.1 Drug Snapshot
 - 6.2.1.1 Originator
 - 6.2.1.2 Collaborator/Co-Developer
 - 6.2.1.3 Route of Administration
 - 6.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 6.2.1.5 Area
 - 6.2.1.6 Type of Molecular Entity
- 6.3 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7. DAIICHI SANKYO COMPANY, LIMITED THROMBOEMBOLISM PIPELINE DETAILS

- 7.1 Daiichi Sankyo Company, Limited Business Profile
- 7.2 Daiichi Sankyo Company, Limited Thromboembolism Drug Details
 - 7.2.1 Drug Snapshot
 - 7.2.1.1 Originator
 - 7.2.1.2 Collaborator/Co-Developer
 - 7.2.1.3 Route of Administration
 - 7.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 7.2.1.5 Area
 - 7.2.1.6 Type of Molecular Entity
- 7.3 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8. IONIS PHARMACEUTICALS INC THROMBOEMBOLISM PIPELINE DETAILS

- 8.1 Ionis Pharmaceuticals Inc Business Profile
- 8.2 Ionis Pharmaceuticals Inc Thromboembolism Drug Details
 - 8.2.1 Drug Snapshot
 - 8.2.1.1 Originator
 - 8.2.1.2 Collaborator/Co-Developer
 - 8.2.1.3 Route of Administration
 - 8.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 8.2.1.5 Area
 - 8.2.1.6 Type of Molecular Entity
- 8.3 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9. JANSSEN PHARMACEUTICALS, INC. THROMBOEMBOLISM PIPELINE DETAILS

- 9.1 Janssen Pharmaceuticals, Inc. Business Profile
- 9.2 Janssen Pharmaceuticals, Inc. Thromboembolism Drug Details
 - 9.2.1 Drug Snapshot
 - 9.2.1.1 Originator

- 9.2.1.2 Collaborator/Co-Developer
- 9.2.1.3 Route of Administration
- 9.2.1.4 Orphan Drug/Fast Track/Special Designation
- 9.2.1.5 Area
- 9.2.1.6 Type of Molecular Entity
- 9.3 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10. LEE'S PHARMACEUTICAL HOLDINGS THROMBOEMBOLISM PIPELINE DETAILS

- 10.1 Lee's Pharmaceutical Holdings Business Profile
- 10.2 Lee's Pharmaceutical Holdings Thromboembolism Drug Details
 - 10.2.1 Drug Snapshot
 - 10.2.1.1 Originator
 - 10.2.1.2 Collaborator/Co-Developer
 - 10.2.1.3 Route of Administration
 - 10.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 10.2.1.5 Area
 - 10.2.1.6 Type of Molecular Entity
- 10.3 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11. PFIZER INC THROMBOEMBOLISM PIPELINE DETAILS

- 11.1 Pfizer Inc Business Profile
- 11.2 Pfizer Inc Thromboembolism Drug Details
 - 11.2.1 Drug Snapshot
 - 11.2.1.1 Originator
 - 11.2.1.2 Collaborator/Co-Developer
 - 11.2.1.3 Route of Administration
 - 11.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 11.2.1.5 Area

- 11.2.1.6 Type of Molecular Entity
- 11.3 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12. PROTHIX BV THROMBOEMBOLISM PIPELINE DETAILS

- 12.1 Prothix BV Business Profile
- 12.2 Prothix BV Thromboembolism Drug Details
 - 12.2.1 Drug Snapshot
 - 12.2.1.1 Originator
 - 12.2.1.2 Collaborator/Co-Developer
 - 12.2.1.3 Route of Administration
 - 12.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 12.2.1.5 Area
 - 12.2.1.6 Type of Molecular Entity
- 12.3 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13. QUERCEGEN PHARMACEUTICALS LLC THROMBOEMBOLISM PIPELINE DETAILS

- 13.1 Quercegen Pharmaceuticals LLC Business Profile
- 13.2 Quercegen Pharmaceuticals LLC Thromboembolism Drug Details
 - 13.2.1 Drug Snapshot
 - 13.2.1.1 Originator
 - 13.2.1.2 Collaborator/Co-Developer
 - 13.2.1.3 Route of Administration
 - 13.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 13.2.1.5 Area
 - 13.2.1.6 Type of Molecular Entity
- 13.3 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action

13.6 Clinical/Pre-clinical Trial Details

13.7 Latest Drug Developments

14. ROCHE HOLDING AG THROMBOEMBOLISM PIPELINE DETAILS

14.1 Roche Holding AG Business Profile

14.2 Roche Holding AG Thromboembolism Drug Details

14.2.1 Drug Snapshot

14.2.1.1 Originator

14.2.1.2 Collaborator/Co-Developer

14.2.1.3 Route of Administration

14.2.1.4 Orphan Drug/Fast Track/Special Designation

14.2.1.5 Area

14.2.1.6 Type of Molecular Entity

14.3 Current Status

14.4 Drug Overview

14.5 Drug Mechanism of Action

14.6 Clinical/Pre-clinical Trial Details

14.7 Latest Drug Developments

15. SHANDONG TAIBANG BIOLOGICAL PRODUCTS CO.LTD. THROMBOEMBOLISM PIPELINE DETAILS

15.1 Shandong Taibang Biological Products Co.Ltd. Business Profile

15.2 Shandong Taibang Biological Products Co.Ltd. Thromboembolism Drug Details

15.2.1 Drug Snapshot

15.2.1.1 Originator

15.2.1.2 Collaborator/Co-Developer

15.2.1.3 Route of Administration

15.2.1.4 Orphan Drug/Fast Track/Special Designation

15.2.1.5 Area

15.2.1.6 Type of Molecular Entity

15.3 Current Status

15.4 Drug Overview

15.5 Drug Mechanism of Action

15.6 Clinical/Pre-clinical Trial Details

15.7 Latest Drug Developments

16. TEARX LTD. THROMBOEMBOLISM PIPELINE DETAILS

- 16.1 TeaRx Ltd. Business Profile
- 16.2 TeaRx Ltd. Thromboembolism Drug Details
 - 16.2.1 Drug Snapshot
 - 16.2.1.1 Originator
 - 16.2.1.2 Collaborator/Co-Developer
 - 16.2.1.3 Route of Administration
 - 16.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 16.2.1.5 Area
 - 16.2.1.6 Type of Molecular Entity
- 16.3 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17. VERSEON CORP THROMBOEMBOLISM PIPELINE DETAILS

- 17.1 Verseon Corp Business Profile
- 17.2 Verseon Corp Thromboembolism Drug Details
 - 17.2.1 Drug Snapshot
 - 17.2.1.1 Originator
 - 17.2.1.2 Collaborator/Co-Developer
 - 17.2.1.3 Route of Administration
 - 17.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 17.2.1.5 Area
 - 17.2.1.6 Type of Molecular Entity
- 17.3 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18. LATEST THROMBOEMBOLISM DRUG PIPELINE DEVELOPMENTS, 2019

19. APPENDIX

- 19.1 About Us
- 19.2 Sources and Methodology

19.3 Contact Information

I would like to order

Product name: 2019 Future of Thromboembolism R&D Pipeline Drugs and Companies- Analysis of Global Thromboembolism Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/21D88AAD9F5EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/21D88AAD9F5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970